Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Pulmonary hypertension
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(290)
•••
Comment by Moonshiner592on Jul 14, 2021 9:24am
124 Views
Post# 33541557

RE:Pulmonary hypertension

RE:Pulmonary hypertension
AngelaL wrote:

I have been scouring the scientific literature to see if there is any drug, approved or in development, that can reverse pulmonary hypertension, so that the disease is fixed, not just temporarily helped while the drug is being taken.


I can find none. 

There are a bunch of drugs out there that lower pulmonary pressure but as soon as you stop taking them the pulmonary blood pressure goes right back up to where it was before the drug was started. 

In the same animal models of pulmonary hypertension, R-107 is different, based on the press release from Claritas last month. It said that R-107 fixes the blood pressure in the lung so that it stays low even after stopping R-107.

As far as I can tell, and I read about 150 articles, everything I could get my hands on through MEDLINE, there is no other drug that has ever been shown to do this. R-107 appears therefore to be a cure, not a temporary fix.  


 



Take a bow Angela for taking some initiative on this research... we may have something "huge" here given the worldwide patent Claritas has ... and ... let's not forget Sepsis and mRNA ...

Exciting times ahead ... looking forward to the upcoming weeks ... 

Go Clas .. GO!! 


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities